US FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosis: New York Saturday, July 12, 2025, 15:00 Hrs [IST] Klotho Neurosci ...

Explore Our Free-Market Analysis Sample – Instant Access: – https://www.astuteanalytica.com/request-sample/amyotrophic-lateral-sclerosis-treatment-market ...

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today ...

The amount of lives that he touched and changed for the better number in the thousands," his stepdaughter wrote.

Klotho is advancing its ALS gene therapy candidate KLTO‑202 to the manufacturing phase, and is planning the first human ...

Stem cell tech simulates ALS, quantum tools decode quasicrystals, and cancer exploits a human mutation—three breakthroughs ...

The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...

Investing.com -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) stock surged 22% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its ...

Documenting his experiences has proven to be the outlet Darin Nakakihara needs in the wake of his ALS diagnosis.

A new study published in JAMA Neurology suggests that commonly prescribed medications for anxiety, depression, and sleep ...

Shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) surged 22% following news that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s gene therapy ...

Doctors are using a new gene therapy drug from the US, hoping to extend Ms Sabrina's lifespan. Read more at straitstimes.com. Read more at straitstimes.com.